Removal of cardiac AL amyloid with positive remodelling of cardiomyocytes and of restrictive cardiomyopathy.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
12 2022
Historique:
revised: 01 06 2022
received: 18 01 2022
accepted: 03 06 2022
pubmed: 4 9 2022
medline: 24 12 2022
entrez: 3 9 2022
Statut: ppublish

Résumé

Herein, we describe histological mobilization of light chain cardiac amyloid documented by sequential left ventricular endomyocardial biopsies. These findings were associated with positive remodelling of cardiomyocytes and of restrictive cardiomyopathy resulting from 14 courses of chemotherapy over 17 years of time. Histological and ultrastructural findings of light chain cardiac amyloid removal led to increase in cardiomyocyte dimension and electrocardiogram voltages, reduction of biventricular wall thickness with improvement of left ventricular diastolic function, and NYHA class shifting from III to I.

Identifiants

pubmed: 36056647
doi: 10.1002/ehf2.14017
pmc: PMC9773750
doi:

Substances chimiques

Amyloid 0

Types de publication

Case Reports Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4330-4334

Informations de copyright

© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

JACC Cardiovasc Imaging. 2014 Mar;7(3):254-63
pubmed: 24560214
N Engl J Med. 1980 Jun 5;302(23):1283-92
pubmed: 6154243
ESC Heart Fail. 2022 Dec;9(6):4330-4334
pubmed: 36056647
JACC CardioOncol. 2019 Sep 24;1(1):117-130
pubmed: 34396169
Circulation. 1997 Aug 19;96(4):1180-4
pubmed: 9286947
Circulation. 2007 Nov 6;116(19):2216-33
pubmed: 17959655
N Engl J Med. 1980 Jun 12;302(24):1333-43
pubmed: 6990257
Eur J Heart Fail. 2021 Jun;23(6):854-871
pubmed: 34010472

Auteurs

Andrea Frustaci (A)

Department of Clinical, Internal, Anesthesiologist and Cardiovascular Sciences, Sapienza University, Rome, Italy.
Cellular and Molecular Cardiology Lab, IRCCS L. Spallanzani, Rome, Italy.

Romina Verardo (R)

Cellular and Molecular Cardiology Lab, IRCCS L. Spallanzani, Rome, Italy.

Nicola Galea (N)

Department of Experimental Medicine, Sapienza University, Rome, Italy.

Maria Alfarano (M)

Department of Clinical, Internal, Anesthesiologist and Cardiovascular Sciences, Sapienza University, Rome, Italy.

Luigi Sansone (L)

MEBIC Consortium, San Raffaele University and IRCCS San Raffaele Roma, Rome, Italy.

Matteo Antonio Russo (MA)

MEBIC Consortium, San Raffaele University and IRCCS San Raffaele Roma, Rome, Italy.

Cristina Chimenti (C)

Department of Clinical, Internal, Anesthesiologist and Cardiovascular Sciences, Sapienza University, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH